指南与共识临床生化临床免疫质量管理与危急值

急性冠脉综合征中肌钙蛋白检测的临床实验室实践建议:AACC与IFCC专家共识

Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine.
指南 / 共识 · Clin Chem · 2018-01-17

该专家共识由美国临床化学协会(AACC) academy与国际临床化学和检验医学联合会(IFCC)生物标志物临床应用工作组合作制定,聚焦高敏肌钙蛋白(hs-cTn)检测的临床实验室实践建议,涵盖质量控制、可报告低限验证、报告单位、性别特异性99百分位参考上限、hs-cTn检测标准、临床沟通、检测记录、标准化、报告时间及连续检测变化等10个主题。

要点

  • hs-cTn检测需验证可报告低限,并使用性别特异性99百分位参考上限定义参考区间。
  • 实验室应关注质控、报告单位统一,并与临床沟通前分析与分析问题对结果的影响。
  • 连续检测hs-cTn浓度变化需结合分析变异与生物学变异解读。

核心结论

  • 针对hs-cTn检测,共识提出临床实验室应关注质量控制、可报告低限验证、性别特异性99百分位参考上限等10个实践主题。

研究设计与样本

  • 该文件为专家共识,由AACC Academy与IFCC TF-CB合作制定,采用专家意见证据级别,聚焦临床实验室实践建议。

主要发现

  • 共识涵盖质控利用、低限验证、报告单位、性别特异性99百分位参考上限、hs-cTn定义标准、临床沟通、检测记录、标准化、报告时间及连续检测变化解读等10个主题。

关键数值与推荐

  • 共识推荐使用性别特异性99百分位作为hs-cTn参考上限,并要求验证可报告低限。
  • 共识建议实验室与临床沟通前分析与分析问题对结果的影响,并记录hs-cTn检测的前分析与分析变量。
  • 共识涉及hs-cTn结果报告时间及连续检测中分析变异与生物学变异的作用。

临床怎么用

  • 实验室应按共识建议进行hs-cTn检测的质量控制、低限验证和性别特异性参考区间报告。
  • 实验室应加强与临床沟通,教育临床医生关于前分析与分析问题对hs-cTn结果的影响。
  • 实验室应规范记录hs-cTn检测的前分析与分析变量,并关注连续检测结果的变化解读。

局限性

  • 该共识基于专家意见证据级别,未提供具体研究数据或系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This document is an essential companion to the third iteration of the National Academy of Clinical Biochemistry [NACB,8 now the American Association for Clinical Chemistry (AACC) Academy] Laboratory Medicine Practice Guidelines (LMPG) on cardiac markers. The expert consensus recommendations were drafted in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine Task Force on Clinical Applications of Bio-Markers (IFCC TF-CB). We determined that there is sufficient clinical guidance on the use of cardiac troponin (cTn) testing from clinical practice groups. Thus, in this expert consensus document, we focused on clinical laboratory practice recommendations for high-sensitivity (hs)-cTn assays. This document utilized the expert opinion class of evidence to focus on the following 10 topics: (a) quality control (QC) utilization, (b) validation of the lower reportable analytical limits, (c) units to be used in reporting measurable concentrations for patients and QC materials, (d) 99th percentile sex-specific upper reference limits to define the reference interval; (e) criteria required to define hs-cTn assays, (f) communication with clinicians and the laboratory's role in educating clinicians regarding the influence of preanalytic and analytic problems that can confound assay results, (g) studies on hs-cTn assays and how authors need to document preanalytical and analytical variables, (h) harmonizing and standardizing assay results and the role of commutable materials, (i) time to reporting of results from sample receipt and sample collection, and (j) changes in hs-cTn concentrations over time and the role of both analytical and biological variabilities in interpreting results of serial blood collections.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Wu AHB, Christenson RH, Greene DN, et al. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018. PMID: 29343532. doi:10.1373/clinchem.2017.277186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。